MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
September 8, 2006
Brian Lawler
Ligand's Drug Sale For the pharmaceutical's marketed drugs, everything must go. Investors, take note. mark for My Articles similar articles
The Motley Fool
April 4, 2007
Brian Lawler
Companies That Pay Out ... and Drop Here is an explanation of why a stock price falls after a large one-time dividend payout. mark for My Articles similar articles
The Motley Fool
May 7, 2008
Brian Lawler
PDL Delivers a Dividend The drugmaker's investors get a hefty payout. mark for My Articles similar articles
The Motley Fool
November 13, 2006
Brian Lawler
King Not Loving Its Shareholders King Pharmaceuticals appears to be a company with stagnating operations, trying to grow sales via licensing or acquiring new drugs, with (at best) a shaky handling of its accounting practices. Investors, take note. mark for My Articles similar articles
The Motley Fool
April 14, 2008
Brian Lawler
PDL BioPharma's Split Decision PDL BioPharma is finally taking further steps to try to realize better value for the different parts of its business. mark for My Articles similar articles
The Motley Fool
March 5, 2008
Brian Lawler
PDL Taken Off the Block Yesterday, PDL BioPharma announced that it had failed to find an acquirer; instead, it will launch another round of restructuring. mark for My Articles similar articles
The Motley Fool
March 26, 2007
Rich Duprey
Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note. mark for My Articles similar articles
The Motley Fool
June 23, 2008
Brian Lawler
Wait a Little Longer, Ligand The FDA delays its review of GlaxoSmithKline and partner Ligand Pharmaceutical's blood-disorder drug Promacta. mark for My Articles similar articles
The Motley Fool
August 6, 2004
Zeke Ashton
Are Biotechs Worth the Risk? Even when their drugs are doing well, companies in this industry don't necessarily yield big rewards for investors. mark for My Articles similar articles
The Motley Fool
September 24, 2007
Brian Lawler
Seismic Shifts at PDL No matter what its hedge fund owner, Third Point, decides it wants to do with PDL, one thing is clear: A year from now, PDL BioPharma will not be the same drugmaker that it is today. Investors, take note. mark for My Articles similar articles
The Motley Fool
April 28, 2011
Brian Orelli
Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable. mark for My Articles similar articles
The Motley Fool
March 3, 2009
Robert Steyer
Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company. mark for My Articles similar articles
The Motley Fool
August 3, 2004
Charly Travers
Black Cloud Over Ligand The pharmaceuticals company misses estimates and loses an auditor. Many investors are going to be skeptical about whether guidance will be met. mark for My Articles similar articles
The Motley Fool
April 18, 2007
Rick Aristotle Munarriz
A Funky New Topping at Domino's Domino's will be sending its shareholders a special one-time dividend next month. But remember that there's no free lunch. mark for My Articles similar articles
The Motley Fool
December 7, 2011
Dan Caplinger
Has PDL BioPharma Become the Perfect Stock? Having moved from special dividends to a pure regular-dividend payout has improved income visibility for shareholders. mark for My Articles similar articles
The Motley Fool
November 2, 2006
Rich Duprey
Eisai Profits From Demand The Japanese pharmaceutical reports strong profits on increased demand for Alzheimer's treatment. Investors, take note. mark for My Articles similar articles
The Motley Fool
June 27, 2008
What's a Dividend? Some companies repay your investment with cold, hard cash. mark for My Articles similar articles
The Motley Fool
February 17, 2005
What's a Dividend? A dividend is a portion of a company's earnings that the firm pays out to its shareholders. mark for My Articles similar articles
The Motley Fool
May 29, 2008
Brian Lawler
Ligand Loses, for Now The FDA sends Ligand Pharmaceutical this message: approval unlikely, try again later. mark for My Articles similar articles
The Motley Fool
March 25, 2009
Brian Orelli
The FDA Leaves Pfizer in the Waiting Room The EU loves its new osteoporosis drug, but what about the U.S.? mark for My Articles similar articles
The Motley Fool
August 13, 2008
Selena Maranjian
Look Beyond the Headlines For dividend investors, the recent news that Stanley Works hiked its dividend for the 41st straight year sounds downright enticing. But the headlines alone don't tell the whole story. Read on for more. mark for My Articles similar articles
The Motley Fool
December 14, 2007
Claire Stephanic
The Best Returns Possible High yield + low payout ratio = superior long-term investment. mark for My Articles similar articles
The Motley Fool
July 30, 2004
Ben McClure
AT&T's Kindest Cut A big dividend cut at Ma Bell is long overdue. Without it, shareholders could be headed for even more trouble. mark for My Articles similar articles
The Motley Fool
August 19, 2011
Cindy Johnson
12 Biotech Stocks the Insiders Are Buying Folks in the know think these biotech stocks will rise. Should you join them? mark for My Articles similar articles
The Motley Fool
March 2, 2009
Dan Caplinger
7 Stocks With Dividends That Should Survive Don't get caught by a dividend cut. mark for My Articles similar articles
The Motley Fool
June 17, 2008
Tom Hutchinson
Will Bank of America Cut the Dividend? What costs will Bank of America endure to keep its payout intact? mark for My Articles similar articles
The Motley Fool
May 15, 2007
Rich Duprey
Eisai Doles Out Tough Medicine The Japanese pharmaceutical company wins a patent infringement decision regarding its heartburn treatment. Investors, take note. mark for My Articles similar articles
The Motley Fool
February 5, 2009
Brian Orelli
Glaxo Cuts Jobs, Guidance -- and the Kitchen Sink With sales dropping, more cuts were inevitable. mark for My Articles similar articles
The Motley Fool
June 8, 2007
Joe Magyer
Avoid the Next Dividend Implosion Dividend stocks may have a reputation of being safe or stodgy, but sometimes they're anything but. Here are three keys to help you spot a dividend cut from a mile away. mark for My Articles similar articles
The Motley Fool
August 25, 2008
Ilan Moscovitz
The Next 2 Dividend Blowups? Nearly 100 companies cut their dividends during the second quarter, the biggest quarterly decline since 1991. Who might be next? mark for My Articles similar articles
The Motley Fool
September 18, 2009
Dan Caplinger
These Stocks Are Growing in All the Right Ways These good dividend stocks have the earnings to back up their payouts: Monsanto... McDonald's... Microsoft... Lockheed Martin... CSX... IBM... mark for My Articles similar articles
The Motley Fool
February 8, 2010
Selena Maranjian
Good News About the Worst Year It's over. Remember, the overall trend of the market is up. When stocks of good, healthy, and growing companies get beaten down, they're likely to regain their footing. mark for My Articles similar articles
The Motley Fool
January 24, 2008
Selena Maranjian
Which Dividends Can You Count On? Some dividends are safe; while others are at risk. mark for My Articles similar articles
The Motley Fool
July 25, 2008
Dan Dzombak
3 Stocks Hitting High Notes These stocks are bucking the trend. mark for My Articles similar articles
Chemistry World
November 7, 2014
Katrina Kramer
Stressed ligands switch catalysis selectivity Researchers have discovered that enantioselectivity in palladium-catalyzed reactions depends on the ligand's intramolecular strain. mark for My Articles similar articles